Related Experiment Video
Updated: Jun 9, 2026
In Utero Intra-cardiac Tomato-lectin Injections on Mouse Embryos to Gauge Renal Blood Flow
Published on: February 4, 2015
A case report of prenatal exposure to rosuvastatin and telmisartan
Yannis Trakadis1, Susan Blaser, Cecil D Hahn
1Division of Clinical and Metabolic Genetics;
Insights
Prenatal exposure to rosuvastatin during pregnancy may be linked to severe developmental issues in newborns. Further research is needed to confirm the safety of statins and sartans during gestation.
Area of Science:
- Pharmacology
- Developmental Pediatrics
- Teratology
Background:
- Statins are a cornerstone therapy for hyperlipidemia, but concerns exist regarding their in utero safety.
- Previous reports have suggested potential links between prenatal statin exposure and birth defects, though causality remains debated.
Observation:
- A case report details a 22-month-old boy with severe microcephaly, growth retardation, dysmorphic features, global developmental delay, and polymicrogyria.
- The infant's mother used telmisartan for seven months and rosuvastatin throughout her pregnancy.
- The infant showed no signs of sartan-associated fetopathy, such as oligohydramnios or renal issues.
Findings:
- The presented case suggests a potential association between prenatal rosuvastatin exposure and severe neurodevelopmental abnormalities.
- Absence of sartan-related anomalies in this case warrants careful consideration of the specific drug and exposure timing.
Implications:
- Increased prevalence of dyslipidemia and hypertension in young women necessitates urgent evaluation of prenatal statin and sartan safety.
- This case highlights the need for comprehensive safety data to guide prescribing practices for lipid-lowering and antihypertensive medications during pregnancy.
Abstract:
Statins are considered to be a standard treatment for hyperlipidemia. Central nervous system, limb and midline defects have been reported in newborns exposed to statins in utero, although causality has been questioned. A 22-month-old boy with severe microcephaly, growth retardation, dysmorphic features, profound global developmental delay and peri-Sylvian polymicrogyria on brain imaging is presented. He was born to a mother exposed to telmisartan during the first seven months and rosuvastatin throughout the entire pregnancy. There were no features of fetopathy associated with sartans including telmisartan, such as a history of oligohydraminios and renal abnormalities. Given the increasing prevalence of obesity and its related complications (including dyslipidemias and hypertension) in young women of childbearing age, more safety data for prenatal exposure to statins and sartans are urgently needed.
